Protein Design Labs, Inc.

William P Schneider

Cary L Queen

Harold E Selick

Maximiliano Vasquez

Man Sung Co

Nicholas F Landolfi

Kathleen L Coelingh

Fas ligand fusion proteins comprising a polypeptide capable of specifically binding an antigen or a cell surface marker are prepared employing recombinant DNA technology for use in, e.g., treatment of autoimmune disorders.

FAS ligand fusion proteins and their uses

Novel methods for producing, and compositions of, humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immunoglobulin chain will usually comprise, in addition to the CDR's, amino acids from the donor immunoglobulin framework that are, e.g., capable of interacting with the CDR's to effect binding affinity, such as one or more amino acids which are immediately adjacent to a CDR in the donor immunoglobulin or those within about about 3 .ANG. as predicted by molecular modeling. The heavy and light chains may each be designed by using any one or all of various position criteria. When combined into an intact antibody, the humanized immunoglobulins of the present invention will be substantially non-immunogenic in humans and retain substantially the same affinity as the donor immunoglobulin to the antigen, such as a protein or other compound containing an epitope.

Humanized immunoglobulins

Polynucleotides encoding improved humanized immunoglobulins

Growing community of inventors

Mountain View, CA, United States of America

William P Schneider